FYN and cancer: However, although several inhibitors of other members of the Src kinase family have been developed for the treatment of cancer [100] and one of these inhibitors is being tested in a clinical trial for AD [101, 102], we are unaware of drugs that selectively inhibit Fyn, but none of the other members of the Src kinase family, and that also effectively penetrate the blood-brain barrier.